Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, molecular diagnostics company Exact Sciences (NASDAQ:EXAS) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Exact Sciences and see what CAPS investors are saying about the stock right now.

Exact Sciences facts

 

 

Headquarters (founded)

Madison, Wis. (1995)

Market Cap

$612.1 million

Industry

Biotechnology

Trailing-12-Month Revenue

$4.1 million

Management

CEO Kevin Conroy

CFO Maneesh Arora

Return on Equity (average, past 3 years)

(47.9%)

Cash/Debt

$108.1 million / $2.0 million

Competitors

CRH Medical

PreMD

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 16% of the All-Star members who have rated Exact Sciences believe the stock will underperform the S&P 500 going forward.

Earlier this week, one of those Fools, zzlangerhans, touched on the stock's seemingly unsustainable valuation:

A [$600M] market cap is way too much for unconvincing sensitivity and specificity data that don't provide a convincing basis for widespread adoption of the Cologuard test. Exact is once again a trader's football and I expect the stock to move with the winds until a concrete catalyst emerges.